Analyst firms · Leerink Partners · IONS
Leerink Partners IONS price target and rating history
Ionis Pharmaceuticals Inc. (IONS) · Health Care
Leerink Partners rates Ionis Pharmaceuticals Inc. (IONS) Outperform with a $62 price target, as of its latest action on Jul 24, 2024. It has published 6 rating actions on IONS since August 2021, including 1 upgrade and 0 downgrades. Across 6 firms with a IONS price target in the last 12 months, the median target is $99.50.
- Current rating
- Outperform
- Price target
- $62
- Median target, all firms
- $99.50
- Actions on IONS
- 6
Leerink Partners price target on IONS
Every Leerink Partners rating on IONS
- Jul 24, 2024
- Feb 25, 2022
- Dec 17, 2021
- Dec 8, 2021
- Nov 4, 2021
- Aug 5, 2021
How other firms rate IONS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BMO Capital Markets | Outperform | $66 | Oct 22, 2026 |
| UBS | Buy | $88 | Oct 15, 2026 |
| Wolfe Research | Peer Perform | Jul 16, 2026 | |
| Citigroup | Buy | $115 | May 19, 2026 |
| Canaccord Genuity | Buy | $110 | Apr 21, 2026 |
| Raymond James | Outperform | $104 | Apr 10, 2026 |
| Barclays | Overweight | $95 | Jan 28, 2026 |
Questions about Leerink Partners and IONS
- What is Leerink Partners's price target for IONS?
- Leerink Partners's latest stated price target for Ionis Pharmaceuticals Inc. (IONS) is $62, from its action on Jul 24, 2024.
- What is Leerink Partners's rating on IONS?
- Leerink Partners rates IONS Outperform, a bullish rating, as of Jul 24, 2024.
- When did Leerink Partners last change its view on IONS?
- On Jul 24, 2024, Leerink Partners upgrades to Outperform from Market Perform, price target $53 to $62.
- How does Leerink Partners's IONS target compare with other analysts?
- Across 6 firms with a IONS price target in the last 12 months, the median target is $99.50.
More IONS rating histories
All Leerink Partners ratingsIONS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.